Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements are consistent with the label (statin-related myopathy/rhabdomyolysis risk; interactions increased with certain drugs; need for caution and symptom reporting). However, several diuretic-specific interaction claims (thiazide/loop effects, comparative risk, high-dose diuretic concern, and 'liver function and muscle enzyme monitoring' as a direct requirement for this interaction) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels in the blood.
Mechanism of action (Section 12.1) and lipid-lowering indications (Section 1.2) support that LIPITOR is a statin and reduces lipids (total-C/LDL-C etc.).
Atorvastatin works by blocking the production of cholesterol in the liver, thereby reducing the amount of cholesterol in the bloodstream.
Mechanism of action (Section 12.1) states LIPITOR is an inhibitor of HMG-CoA reductase (cholesterol synthesis pathway). Label excerpts do not explicitly say 'in the liver' or 'production of cholesterol in the liver,' but the HMG-CoA reductase inhibition is consistent with cholesterol synthesis reduction.
Lipitor (atorvastatin) can increase the risk of muscle damage (myopathy) when taken with certain diuretics.
Skeletal muscle warning notes statins can cause myopathy and rare rhabdomyolysis (Section 5.1). However, the 'diuretics' specificity is not supported in provided excerpts (see unsupported).
Monitoring liver function and muscle enzymes is important when taking Lipitor and diuretics together.
Label excerpt includes liver dysfunction with transaminase elevations (Section 5.2), and skeletal muscle warning (Section 5.1). The provided excerpt does not explicitly require 'muscle enzymes' monitoring or link it specifically to diuretic coadministration.
Muscle pain, weakness, or tenderness should be reported to a healthcare provider when taking Lipitor and diuretics together.
Skeletal muscle warning (Section 5.1) discusses myopathy/rhabdomyolysis and temporarily withholding/discontinuing for acute serious condition suggestive of myopathy; label excerpt supports the concept of clinical action for suspected myopathy symptoms, though it does not list 'pain, weakness, or tenderness' specifically.
Lipitor and diuretics can be taken together, but monitoring liver function and muscle enzymes and adjusting the medication regimen as needed is essential.
The label excerpt supports that statin myopathy risk increases with certain interacting drugs and that therapy may need to be withheld/discontinued in myopathy (Section 5.1) and that liver transaminase elevations occur (Section 5.2). The 'diuretics can be taken together' portion is not supported by provided drug-interaction excerpts.
Unsupported Statements
Lipitor (atorvastatin) can increase the risk of muscle damage (myopathy) when taken with certain diuretics.
The provided Drug Interactions section (Section 7 and subsections) lists specific interacting drugs (fibric acid derivatives, niacin, cyclosporine, strong CYP 3A4 inhibitors like clarithromycin/itraconazole, and grapefruit juice). Diuretics (thiazide/loop) are not mentioned in the supplied excerpts.
Thiazide diuretics can increase the levels of atorvastatin in the blood, potentially leading to muscle damage.
No thiazide-specific interaction or plasma level increase is provided in the supplied label excerpts.
Loop diuretics can increase the levels of atorvastatin in the blood.
No loop diuretic-specific interaction or plasma level increase is provided in the supplied label excerpts.
The risk of muscle damage with loop diuretics is lower compared to thiazide diuretics.
No comparative risk or diuretic class comparison is provided in the supplied label excerpts.
The interaction between Lipitor and diuretics is a concern, particularly for patients taking high doses of diuretics.
No diuretic interaction is described in the supplied label excerpts; no 'high dose diuretics' guidance is provided.
Regular blood tests can detect changes in liver function that may indicate an interaction between Lipitor and diuretics.
Section 5.2 reports transaminase elevations; however, the supplied excerpts do not describe blood testing as a detection method for a specific 'diuretic interaction' nor provide interaction-specific monitoring instructions for diuretics.
A healthcare provider may need to adjust the medication dosage or switch to a different diuretic to minimize the risk of interaction between Lipitor and diuretics.
The supplied label excerpts provide specific dose limits for certain interacting drugs (e.g., cyclosporine; caution with clarithromycin for doses >20 mg), but do not provide diuretic-specific switching/adjustment instructions.
Lipitor has been associated with over 1,000 reported interactions with other medications, including diuretics.
The provided label excerpts do not quantify the number of interactions or mention diuretics in that context.
Pravastatin is a statin medication that may be less likely to interact with diuretics.
The supplied label excerpts are for LIPITOR only and do not discuss comparative interaction likelihood between statins or diuretic interactions for pravastatin.
Rosuvastatin is another statin medication that may be a safer alternative.
The supplied label excerpts do not discuss rosuvasatin safety or comparative interaction risk versus LIPITOR.
The risk of muscle damage from taking Lipitor and diuretics can be minimized by monitoring liver function, watching for muscle pain, and adjusting the medication regimen as needed.
The label excerpt supports monitoring/clinical management related to muscle and liver issues generally (Sections 5.1 and 5.2), but it does not provide a diuretic-specific risk minimization plan or mention diuretics.
Contradictions
Important Omissions
Specific diuretic interaction statements are not supported by the provided label excerpts; to be label-aligned, the response should instead reference the label-listed interacting agents (fibric acid derivatives, niacin, cyclosporine, strong CYP 3A4 inhibitors such as clarithromycin/itraconazole, and grapefruit juice).
Importance:
Moderate
No mention of label-supported dose cautions/limits for specific interacting drugs (e.g., cyclosporine dose not exceeding 10 mg; caution with clarithromycin when LIPITOR dose exceeds 20 mg).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Diuretic-specific interaction claims (thiazide/loop) are unsupported by the provided LIPITOR label excerpts. This could lead to incorrect expectations about when interactions occur and what monitoring/adjustments are necessary.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple diuretic-specific interaction, plasma level, comparative risk, high-dose diuretic, and 'safer alternative statin' claims are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or qualify diuretic-specific claims and align interaction content to the label-provided interacting drugs/classes (fibric acid derivatives, niacin, cyclosporine; strong CYP3A4 inhibitors like clarithromycin/itraconazole; grapefruit juice). For management language, use label-supported guidance such as caution/withholding/discontinuing for suspected myopathy and liver transaminase monitoring based on label warnings.